Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $4.63

Shares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been given a consensus rating of "Hold" by the twelve brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $4.63.

Several research analysts recently weighed in on BLUE shares. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $4.00 target price on shares of bluebird bio in a report on Thursday, August 15th. StockNews.com started coverage on bluebird bio in a research note on Friday, September 27th. They issued a "sell" rating for the company. Wells Fargo & Company decreased their target price on bluebird bio from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research note on Wednesday, September 25th. Bank of America dropped their price target on bluebird bio from $4.00 to $3.00 and set a "buy" rating for the company in a research note on Thursday, August 15th. Finally, Robert W. Baird reduced their price objective on shares of bluebird bio from $7.00 to $6.00 and set an "outperform" rating on the stock in a research report on Thursday, August 15th.

Institutional Trading of bluebird bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLUE. Allegheny Financial Group LTD purchased a new position in bluebird bio during the second quarter valued at $25,000. Enterprise Bank & Trust Co acquired a new position in shares of bluebird bio during the first quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. increased its position in shares of bluebird bio by 189.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 36,580 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 23,933 shares in the last quarter. Sequoia Financial Advisors LLC raised its stake in bluebird bio by 48.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company's stock valued at $51,000 after purchasing an additional 13,000 shares during the last quarter. Finally, Bayesian Capital Management LP purchased a new position in bluebird bio in the 1st quarter valued at $52,000. Institutional investors and hedge funds own 87.43% of the company's stock.

bluebird bio Stock Performance

Shares of NASDAQ:BLUE traded up $0.05 during midday trading on Friday, hitting $0.57. The company had a trading volume of 10,217,580 shares, compared to its average volume of 7,800,922. bluebird bio has a 12-month low of $0.45 and a 12-month high of $5.53. The company has a fifty day moving average of $0.71 and a two-hundred day moving average of $0.94. The company has a market cap of $62.32 million, a price-to-earnings ratio of -0.76 and a beta of 0.75. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.93 and a quick ratio of 0.82.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.